 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 664 | 回復(fù): 0 | |||
caijing1986銅蟲 (初入文壇)
|
[求助]
專業(yè)翻譯英文摘要
|
|
Standard Versus Extended Duration DirectActing Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment Abstract Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow responders affects outcomes. Objectives: The primary objective was to compare SVR rates between traditional and extended duration groups. Secondary objectives were to compare SVR rates among subgroups and to determine factors associated with SVR. Methods: This institutional review board–approved, retrospective, single-center study identified patients with chronic hepatitis C virus (HCV) infection with detectable week 4 HCV RNA who were treated with DAAs. Patients were excluded for early discontinuation, treatment regimen not recommended first-line, or missing HCV RNA labs. Patients were stratified into traditional and extended duration groups. The primary end point was SVR. Secondary end points included factors associated with SVR and rationale for extension of therapy duration. Results: A total of 363 patients were included; 58 (16%) received extended therapy. Patients were primarily genotype 1a (70%) and treatment naïve (80%). More than half had advanced fibrosis or cirrhosis. SVR12 rates were 100% in the extended duration group and 96.7% in the traditional duration group (P = 0.37). There were no associations with SVR and prespecified patient-specific factors. Sample size was limited. Conclusion and Relevance:Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders. Keywords hepatitis C, response-guided therapy, direct-acting antivirals |
回復(fù)此樓» 猜你喜歡
材料化工求調(diào)劑
已經(jīng)有3人回復(fù)
-
一志愿南京大學(xué)資源與環(huán)境專業(yè)283分求調(diào)劑
已經(jīng)有8人回復(fù)
-
085600材料與化工 292分 求調(diào)劑
已經(jīng)有6人回復(fù)
-
材料調(diào)劑
已經(jīng)有12人回復(fù)
-
334求調(diào)劑
已經(jīng)有6人回復(fù)
-
申博
已經(jīng)有6人回復(fù)
-
接受26屆調(diào)劑生
已經(jīng)有14人回復(fù)
-
專碩數(shù)二英二0854總分317，過六級，有電賽國賽江蘇省二，省級大創(chuàng)，論文等
已經(jīng)有16人回復(fù)
-
070300調(diào)劑一志愿南京大學(xué)化學(xué)專業(yè)，初試273分，有論文有專利有競賽，求調(diào)劑B區(qū)211
已經(jīng)有14人回復(fù)
-
售瀆SCI文章，我:8⊙ 55 1⊙ 54。備注【⊙=0】
已經(jīng)有6人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 caijing1986 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 專碩數(shù)二英二0854總分317，過六級，有電賽國賽江蘇省二，省級大創(chuàng)，論文等 +3 | Zzhiang 2026-02-28 | 16/800 |
|
|---|---|---|---|---|
|
|
[考研] 070300調(diào)劑一志愿南京大學(xué)化學(xué)專業(yè)，初試273分，有論文有專利有競賽，求調(diào)劑B區(qū)211 +4 | 82206202 2026-02-28 | 14/700 |
|
|
[考研]
 調(diào)劑的同學(xué)，走過路過，不要錯過
+4
|
likeihood 2026-03-06 | 6/300 |
|
|
|
[考博] 售瀆SCI文章，我:8⊙ 55 1⊙ 54。備注【⊙=0】 +4 | ipys00zm58 2026-03-06 | 6/300 |
|
|
|
[考研] 308求調(diào)劑 +7 | 倘若起風(fēng)了呢 2026-03-05 | 9/450 |
|
|
|
[考研] 材料學(xué)碩318求調(diào)劑 +21 | February_Feb 2026-03-01 | 24/1200 |
|
|
|
[考研] 085602高分子方向求調(diào)劑 +7 | tlgudy 2026-03-04 | 7/350 |
|
|
|
[考研] 347求調(diào)劑 +6 | 啊歐歐歐 2026-03-03 | 8/400 |
|
|
|
[考研] 材料085600 303求調(diào)劑 +7 | 1bygone 2026-03-04 | 7/350 |
|
|
|
[考研] 環(huán)境調(diào)劑 +7 | 柒槿levana 2026-03-01 | 7/350 |
|
|
|
[考研] 本科太原理工采礦工程，求調(diào)劑 +3 | onlx 2026-03-01 | 3/150 |
|
|
|
[考研] 085601 材料305分求助 +4 | 泡泡郵件 2026-03-03 | 6/300 |
|
|
|
[考研] 0854總分272 +5 | 打小就是老實人 2026-03-02 | 6/300 |
|
|
|
[考研] 276求調(diào)劑 +8 | 路lyh123 2026-02-28 | 10/500 |
|
|
|
[考研]
材料270求調(diào)劑
 6+6
|
Eiiiio 2026-03-01 | 11/550 |
|
|
|
[考研] 268求調(diào)劑 +10 | 簡單點0 2026-03-02 | 14/700 |
|
|
|
[考研]
 計算機(jī)學(xué)碩 分?jǐn)?shù)285求調(diào)劑
+4
|
glwshine 2026-03-02 | 5/250 |
|
|
|
[論文投稿]
通訊作者寫誰，問題是你意想不到的問題
15+3
|
阿爾法啊 2026-03-01 | 3/150 |
|
|
|
[考研] 322求調(diào)劑 +3 | 熊境喆 2026-03-01 | 3/150 |
|
|
|
[考研] 311求調(diào)劑 +6 | 亭亭亭01 2026-03-01 | 6/300 |
|